Navigation Links
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
Date:4/13/2009

fied as either Hodgkin's or non-Hodgkin's lymphoma (NHL). NHL is the most prevalent type of lymphoma: the National Cancer Institute estimates there will be more than 66,000 new cases and over 19,000 deaths from NHL in the United States in 2008. There are many different types of NHL, which are generally divided as either B-cell, the most common, or T-cell NHL. Though treatment of NHL has improved significantly, nearly 25% of patients with B-cell lymphomas do not respond to standard therapy, which generally consists of high-dose radiotherapy, chemotherapy or a combination of both.

About Pharmacyclics

Pharmacyclics(R) is committed to creating and developing novel pharmaceutical products that treat serious unmet medical needs in oncology and autoimmune diseases. Its deep and broad pipeline includes four first in class/best in class drug candidates that are currently under clinical development. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE:

This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from t
'/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
2. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
3. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
6. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
7. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
10. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
11. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... Minn. , July 28, 2015 ANI ... the Company plans to release its second quarter and ... before the opening of the U.S. financial markets. The ... Relations section of the Company,s website, www.anipharmaceuticals.com . ... Chief Executive Officer, and Charlotte C. Arnold , ...
(Date:7/28/2015)... Oncology, Inc. (OTC: CSBR), engaged in the development of ... and use of oncology drugs, today announced its financial ... Fourth Quarter and Recent Business Highlights: , ... period result , Procured a quarterly record high ... Champions Oncology CEO, stated, "The end of fiscal 2015 ...
Breaking Medicine Technology:CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... According to ... able to stop the cycle of addiction in lab mice. The study involving isradipine ... for the new prospect of helping their clients overcome drug and alcohol addictions. The ...
(Date:7/28/2015)... ... July 28, 2015 , ... Bipolar disorder is often associated with mood swings ... times a year. The World Health Organization (WHO) has reported that bipolar disorder affects ... Health reveals that the United States has the highest lifetime rate of bipolar disorder ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... 28, 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta ... Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized ... peers in the metro area as one of the most respected doctors in Reproductive ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed ... the identification of individuals with active yet undetected sub-clinical disease, who are at ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... (HealthDay News) -- In men who,ve had their prostate surgically ... a rise in blood levels of prostate specific antigen (PSA) ... So finds a new study slated to be presented Monday ... in Washington, D.C. The study included 321 smokers ...
... --,More than half of those who develop Alzheimer,s disease before ... signs of the disease are symptoms other than memory problems, ... of 40 people from Barcelona who were found to have ... the age at which the symptoms began, as well as ...
... of workshops held by the Institute of Medicine explored ... to harness the full potential of new digital technologies ... efficiency and apply knowledge to real-time care decisions. , ... for Continuous Improvement in Health and Health Care recaps ...
... strong commitment to medical and health research and recognize ... and the nation,s economy, according to a new statewide ... Ohio Medical University (NEOMED). A strong majority ... important42% say very importantto the state,s economy. Eight in ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
... Researchers at Sandia National Laboratories have developed a ... about exactly how and why a cell,s defenses ... successfully fending off others like E.coli. The approach ... which could open doors to new diagnostic, prevention ...
Cached Medicine News:Health News:Research Shows Early Onset Alzheimer's Disease Sometimes Missed 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 2Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 3
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
The Codman steerable neuroendoscope combines a high quality fiberoptic image with the flexibility and steerability required for many neuroendoscopic applications....
... Optimum visualization of the spine. ... room are provided for all ... the arms in both superior ... spine can be positioned for ...
Adjust-A-Tip cautery....
Medicine Products: